申请人:Research Triangle Institute
公开号:US20130150357A1
公开(公告)日:2013-06-13
The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.
本发明提供了一种羟基丙酮类似物,能够抑制一个或多个单胺的再吸收和/或作为尼古丁乙酰胆碱受体的拮抗剂。这些化合物可以选择性地结合到一个或多个单胺转运体上,包括多巴胺、去甲肾上腺素和5-羟色胺的转运体,和/或可以选择性地结合到一个或多个尼古丁乙酰胆碱受体亚型上。这些化合物可以用于治疗对单胺水平调节和/或尼古丁乙酰胆碱受体拮抗剂敏感的疾病,包括药物依赖、抑郁症和肥胖症。